Practical summary of modern treatments for androgenetic alopecia: best-supported options, what to expect, adverse effects, and when to refer to a dermatologist

Introduction

Androgenetic alopecia is the most common cause of progressive hair thinning in both men and women. In routine practice, management begins by confirming that the pattern is consistent with progressive follicular miniaturization rather than another inflammatory, autoimmune, or scarring alopecia. The recent review on modern treatment of androgenetic alopecia emphasizes careful clinical diagnosis, individualized therapy selection, and long-term follow-up, because response is usually gradual and highly dependent on adherence [1].

Although this article focuses on androgenetic alopecia, not every form of hair loss shares the same biology. Recent reviews on alopecia areata show that patchy, sudden hair loss reflects a distinct autoimmune process with different diagnostic and therapeutic implications [2],[6]. That distinction matters, because the wrong label can delay appropriate treatment.

Which treatments have the best evidence now

Current evidence still places established medical therapy at the center of treatment. The modern review of androgenetic alopecia highlights approaches that prolong the anagen phase and counter androgen-driven effects in susceptible follicles as key options [1]. In practical terms, this means two major therapeutic pillars: growth-promoting therapies and antiandrogenic or androgen-pathway-modulating treatments [1].

Minoxidil, in topical formulations and in selected settings as low-dose oral therapy, remains among the most widely used options because of its role in stimulating growth and improving density in appropriate patients [1]. Finasteride and other antiandrogenic strategies also have an important role, especially when the aim is to slow ongoing follicular miniaturization [1]. The review also makes clear that modern care should not be seen as a one-time intervention, but as a sustained plan, often combining treatments according to sex, age, clinical pattern, and tolerability [1].

In addition, advances in in vitro and in vivo models for androgenetic alopecia drug development are improving understanding of follicle biology and helping evaluate new therapeutic strategies [3]. These models do not replace clinical trials, but they support the concept that future treatment may become more personalized and mechanism-based [3].

What patients should realistically expect

Expectation setting is one of the most important parts of treatment. Improvement in androgenetic alopecia is usually not immediate. In many patients, the initial goal is not full restoration of previous density, but slowing progression, reducing shedding, and achieving visible yet gradual improvement [1]. Clinical response generally requires months of consistent treatment and periodic reassessment [1].

It is also important to explain that outcomes vary. Factors such as disease duration, degree of miniaturization, family history, age, and treatment continuity influence results [1]. Some patients gain density or hair shaft thickness; others mainly achieve stabilization, which is still a meaningful clinical benefit [1].

If the course does not fit the usual story of androgenetic alopecia, the diagnosis should be reconsidered. Alopecia areata can mimic or coexist with other hair loss patterns, and recent reviews emphasize the importance of correct clinical and immunopathogenic assessment [2],[6].

Adverse effects and treatment limitations

Every treatment should be prescribed with a clear discussion of potential benefits and adverse effects. The modern review of androgenetic alopecia stresses individualized prescribing and monitoring of tolerability, especially with systemic therapies [1]. In practical terms, topical therapies may be limited by local irritation or reduced adherence because they require continuous use [1]. Systemic antiandrogenic therapies require consideration of patient profile, contraindications, and clinical follow-up [1].

Another major limitation is that stopping treatment often leads to loss of the benefit achieved, because the condition remains biologically progressive [1]. For that reason, a realistic conversation about long-term maintenance is essential.

It should not be assumed that emerging or immunomodulatory therapies used in autoimmune alopecias are appropriate for androgenetic alopecia. The literature on alopecia areata, including the report of successful treatment with upadacitinib, belongs to a different pathogenic setting driven by autoimmunity and inflammation rather than the core mechanism of androgenetic alopecia [2],[4],[6].

When to refer to a dermatologist

Referral to dermatology is appropriate when the diagnosis is uncertain or when red flags are present. Patients should be referred if hair loss is very rapid, patchy, painful, associated with erythema, marked scale, pustules, or signs of scarring; if eyebrows, eyelashes, or other atypical areas are involved; or if alopecia areata, scarring alopecia, or another scalp disorder is suspected [2],[6].

Referral is also appropriate when there is inadequate improvement despite a well-conducted initial treatment trial, when systemic therapy is being considered, or when diagnostic uncertainty requires trichoscopy, biopsy, or specialist assessment [1]. Modern reviews make clear that accurate classification of alopecia can completely change management [1],[2].

Practical take-home points

In general practice, a reasonable approach is to confirm a pattern compatible with androgenetic alopecia, explain the chronic nature of the condition, start the best-supported treatment based on the patient’s profile, review adherence and tolerability, and reassess over months rather than weeks [1]. Patients should be told that the most common realistic goal is stabilization with partial improvement, not guaranteed full regrowth [1].

If the pattern deviates from expectations, if inflammation is present, if hair loss is patchy, or if the case is treatment-resistant, dermatologic evaluation is the safest next step [1],[2],[6].

References

[1] Authors. [Modern treatment of androgenetic alopecia]. Orvosi hetilap (2026). https://pubmed.ncbi.nlm.nih.gov/42669143/ [2] Authors. Alopecia Areata: Advances in Clinical Evaluation and Pathogenesis. Journal of the American Academy of Dermatology (2026). https://pubmed.ncbi.nlm.nih.gov/42607949/ [3] Authors. In vitro and in vivo models for androgenetic alopecia drug development. Dis Model Mech (2026). https://pubmed.ncbi.nlm.nih.gov/42417552/ [4] Authors. Successful treatment of coexisting alopecia areata and hidradenitis suppurativa with upadacitinib. Anais brasileiros de dermatologia (2026). https://pubmed.ncbi.nlm.nih.gov/42673758/ [5] Authors. Genetic context shapes interpretation of AIRE and Notch4 in alopecia areata. JID innovations : skin science from molecules to population health (2026). https://pubmed.ncbi.nlm.nih.gov/42633099/ [6] Authors. Alopecia areata: an autoimmune insult, molecular insights, and therapeutic horizons. Human immunology (2026). https://pubmed.ncbi.nlm.nih.gov/42628384/